NICE draft guidance says 'no' to Amgen's Repatha
The National Institute for Health and Care Excellence (NICE) the medicines cost watchdog for England and Wales, has today published draft guidance that does not recommend Amgen’s (Nasdaq: AMGN) Repatha (evolocumab) as an option for people with high cholesterol (primary hypercholesterolemia - heterozygous-familial and non-familial) and mixed dyslipidemia.
Primary non-familial hypercholesterolemia affects an estimated 1.5 million people in England. Primary heterozygous-familial hypercholesterolemia is an inherited condition caused by a faulty gene and affects about 106,000 people in England. People with this condition have raised cholesterol levels from birth.
The draft guidance does not recommend evolocumab, alone or in combination with lipid-lowering therapies, for treating primary hypercholesterolemia or mixed dyslipidemia in adults for whom lipid-modifying therapies, in line with current NICE guidance, would be considered.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze